Published in Cancer Prev Res (Phila) on July 01, 2014
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila) (2015) 1.49
Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients. PLoS One (2016) 1.46
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget (2015) 1.06
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies. Mol Cancer Res (2015) 0.97
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat (2014) 0.95
Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol (2014) 0.93
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol (2014) 0.87
Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget (2016) 0.84
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol (2016) 0.83
A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol (2016) 0.83
Why does obesity promote cancer? Epidemiology, biology, and open questions. Ecancermedicalscience (2015) 0.83
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metab (2016) 0.83
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. J Clin Oncol (2016) 0.82
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One (2014) 0.81
Disease drivers of aging. Ann N Y Acad Sci (2016) 0.81
High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget (2016) 0.80
Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2015) 0.80
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia (2017) 0.78
Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. Oncotarget (2015) 0.78
Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prev Res (Phila) (2015) 0.77
Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am (2015) 0.77
Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev (2017) 0.76
Diabetes, Diabetes Treatment, and Risk of Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.76
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol (2016) 0.76
No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study. Medicine (Baltimore) (2017) 0.75
MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS One (2016) 0.75
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore) (2017) 0.75
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep (2016) 0.75
Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. Interface Focus (2017) 0.75
Prognostic value of glycated hemoglobin in colorectal cancer. World J Gastroenterol (2016) 0.75
Using Large Diabetes Databases for Research. J Diabetes Sci Technol (2016) 0.75
Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes Control (2016) 0.75
Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk. PLoS One (2014) 0.75
Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study. Diabetes Ther (2016) 0.75
Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer. Oncol Lett (2017) 0.75
Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract (2016) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Quantitative methods in the review of epidemiologic literature. Epidemiol Rev (1987) 7.40
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med (2002) 6.53
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
A comparison of methods to detect publication bias in meta-analysis. Stat Med (2001) 4.22
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut (2012) 3.56
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol (2011) 2.60
Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer (2008) 2.53
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab (2011) 2.48
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) 2.41
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care (2012) 2.32
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer (2011) 2.30
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) (2012) 2.10
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (2010) 2.04
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab (2013) 1.83
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism (2010) 1.81
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer (2011) 1.70
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog (2010) 1.69
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab (2010) 1.67
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer (2011) 1.64
If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) (2011) 1.61
Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. Diabetes Res Clin Pract (2012) 1.60
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia (2011) 1.59
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2010) 1.55
The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res (2012) 1.53
Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia (2011) 1.53
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2011) 1.44
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care (2012) 1.42
Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol (2008) 1.41
Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev (2010) 1.39
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab (2004) 1.39
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol (2009) 1.33
Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol (2012) 1.29
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care (2006) 1.27
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol (2012) 1.27
Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care (2010) 1.23
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care (2004) 1.21
Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum (2008) 1.20
Metformin for obesity in children and adolescents: a systematic review. Diabetes Care (2009) 1.17
Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer (2012) 1.17
Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer (2011) 1.15
Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism (2013) 1.12
Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol (2012) 1.11
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) (2012) 1.10
The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer (2012) 1.08
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab (2011) 1.04
What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.02
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig Liver Dis (2012) 1.00
Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism (2011) 1.00
Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control (2012) 1.00
Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int (2009) 1.00
The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol (2012) 0.96
Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia (2011) 0.96
Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma (2009) 0.94
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care (2012) 0.94
Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr (2011) 0.94
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract (2010) 0.93
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab (2012) 0.93
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.92
Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract (2013) 0.91
Diabetes, metformin, and breast cancer: lilac time? J Clin Oncol (2012) 0.88
The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes. Diabetes Metab J (2013) 0.86
Propranolol for Off-Label Treatment of Patients With Melanoma: Results From a Cohort Study. JAMA Oncol (2017) 1.38
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol (2016) 1.13
Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol (2014) 0.97
Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer (2014) 0.86
The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis. J Dermatol Sci (2014) 0.82
Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2015) 0.80
High glycemic index and glycemic load are associated with moderately increased cancer risk. Mol Nutr Food Res (2015) 0.80
Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. Int J Cancer (2016) 0.79
Prognostic significance of hematological profiles in melanoma patients. Int J Cancer (2016) 0.77
Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy. PLoS One (2013) 0.77
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. Cancer Prev Res (Phila) (2016) 0.76
Stress Exposure in Significant Relationships Is Associated with Lymph Node Status in Breast Cancer. PLoS One (2016) 0.75
Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. J Invest Dermatol (2016) 0.75
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Res Treat (2016) 0.75
Erratum to: Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: a review of the literature and meta-analysis. Eur J Nutr (2017) 0.75
Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: a review of the literature and meta-analysis. Eur J Nutr (2016) 0.75
Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. Med Oncol (2017) 0.75
A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. Cancer Prev Res (Phila) (2017) 0.75
Role of BMI and hormone therapy in melanoma risk: a case-control study. J Cancer Res Clin Oncol (2017) 0.75
Estrogen receptor (ER)β expression and worse outcome from melanoma in pregnant and perimenopausal women. J Am Acad Dermatol (2016) 0.75
A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. Cancer Prev Res (Phila) (2015) 0.75